Merck, Inc.

🇵🇭Philippines

Country: 🇵🇭Philippines

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001)

Phase 2

Completed

Conditions: Stomach Ulcer
Duodenal Ulcer

First Posted Date: 2007-10-15

Last Posted Date: 2015-06-11

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 462

Registration Number: NCT00543868

MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)

Phase 3

Terminated

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2007-10-12

Last Posted Date: 2015-06-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 247

Registration Number: NCT00543010

A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2007-10-10

Last Posted Date: 2017-02-17

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 330

Registration Number: NCT00541463

A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Matching placebo to sitagliptin
Drug: sitagliptin phosphate (+) metformin hydrochloride
Drug: Matching placebo to pioglitazone
Drug: Matching Placebo to Sita/Met FDC

First Posted Date: 2007-10-10

Last Posted Date: 2017-05-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 492

Registration Number: NCT00541450

Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

First Posted Date: 2007-10-10

Last Posted Date: 2015-10-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 149

Registration Number: NCT00542022

Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: sitagliptin phosphate

First Posted Date: 2007-10-10

Last Posted Date: 2017-05-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 103

Registration Number: NCT00541229

Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Sitagliptin

First Posted Date: 2007-10-10

Last Posted Date: 2015-08-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 273

Registration Number: NCT00541775

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

Phase 1

Terminated

Conditions: Lung Cancer
Gastric Cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer

Interventions: Drug: Docetaxel plus lonafarnib

First Posted Date: 2007-10-05

Last Posted Date: 2015-02-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 5

Registration Number: NCT00539968

A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)

Phase 2

Completed

Conditions: Postoperative Nausea and Vomiting

Interventions: Drug: Rolapitant Dose 4
Drug: Placebo
Drug: Rolapitant Dose 3
Drug: Rolapitant Dose 1
Drug: Rolapitant Dose 2
Drug: Ondansetron

First Posted Date: 2007-10-04

Last Posted Date: 2013-11-01

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 619

Registration Number: NCT00539721

Treatment of Patients With Anxiety Disorder (0777-022)

Phase 2

Completed

Conditions: Generalized Anxiety Disorder

First Posted Date: 2007-10-04

Last Posted Date: 2015-11-01

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 270

Registration Number: NCT00539578

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy